Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Economy & Forex

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

FDA chief Hahn says mid-December vaccine approval just 'possible' - ABC News

12/01/2020 | 05:49pm EST

Dec 1 (Reuters) - U.S. Food and Drug Administration Commissioner Stephen Hahn said on Tuesday it was "possible" the agency could approve Pfizer Inc's COVID-19 vaccine by mid-December if everything falls into place, but that it may take longer.

When asked in an ABC News interview whether a vaccine could be available days or weeks after a planned Dec. 10 meeting in which FDA expert advisers will recommend for or against approval, Hahn said, "it's hard to predict and I want to set the appropriate expectations."

The FDA often follows the recommendations of these advisory panels.

Hahn added: "We should be relatively quick afterward but there could be issues that come up that we have to address."

U.S. Health and Human Services Secretary Alex Azar has said an FDA decision could come days after the Dec. 10 meeting. The Operation Warp Speed program is also planning for the first vaccine shots on Dec. 14.

Pfizer Inc and BioNTech filed with the FDA in November for emergency use authorization of their COVID-19 vaccine.

Asked whether the vaccine could become available the week of Dec. 15 after the advisory panel meets, Hahn would not commit.

“It is possible. We need everything to fall into place."

Hahn confirmed he had met with the White House earlier in the day. Axios reported late on Monday that Hahn had been summoned by Chief of Staff Mark Meadows about the vaccine timing.

Hahn said the purpose of the meeting "was to provide a briefing around exactly the issues we’re discussing here. That’s what occurred.”

Hahn said in the ABC News interview that the FDA's scientists needed to pore over the safety and efficacy data submitted by the companies to reach a decision, as they do in all drug reviews. (Reporting by Rebecca Spalding in New York Editing by Caroline Humer and Matthew Lewis)


© Reuters 2020
Latest news "Economy & Forex"
06:20aS.Africa's biggest coal exporter says 2020 exports fell to 70.2 million tonnes
RE
06:14aFrance's Unemployment Rate Fell in 4Q
DJ
06:11aSterling gets vaccine boost to hit 8-month high vs euro
RE
06:03aFed on hold as officials weigh pandemic against vaccines, fiscal support
RE
05:52aBritain may raise contactless ceiling after pandemic payment surge
RE
05:44aReluctance to Spend Throttles India's Growth Long After Covid-19 Lockdowns Ended
DJ
05:44aFed Likely to Keep Interest Rates Near Zero as Economy Stumbles
DJ
05:43aFACTBOX : The Brexit impact so far: paperwork, process and higher prices
RE
05:42aGold under pressure as dollar rebounds ahead of U.S. Fed verdict
RE
05:38aSINOMACH CHINA NATIONAL MACHINERY INDUSTRY CORPO : CUC incubates Asia's largest waste pyrolysis and gasification project
PU
Latest news "Economy & Forex"